New cocktail of drugs takes on deadly pancreatic cancer
NCT ID NCT07235930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a sequence of chemotherapy drugs plus two immunotherapy and anti-angiogenesis drugs works better than standard chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. About 292 participants in China will be randomly assigned to one of two groups. The goal is to see if the new combination helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nab-paclitaxel, gemcitabine, 5-FU, oxaliplatin, leucovorin, serplulimab, and bevacizumab
What this could lead to
If successful, this combination could extend survival for people with advanced pancreatic cancer who have not had prior treatment.
What could go wrong
This is a Phase III trial, but the new combo adds more drugs, which may increase side effects. It may not prove better than standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact